Axial transverse computerized tomography in 73 glioblastomas

Steinhoff, H.; Grumme, Th.; Kazner, E.; Lange, Sebastian; Lanksch, W.; Meese, Wolfgang; Wüllenweber, R.

doi:10.1007/bf01406630

Cited by 12 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others shared this initial enthusiasm, stating that contrast enhancement on CT scans are "more accurate a prognostic sign than pathology" 7 and that the accu-racy "reached almost that of a brain slice seen at autopsy." 21 However, later investigators found only a partial correlation between contrast enhancement on CT and other imaging modalities; they also found an inconsistent relationship between contrast enhancement and histologic grade. 3 -4 - 9 In a comparison of CT scans and neuropathologic findings in 8 patients, variations in the intensity of enhancement often had no apparent correlation with local differences in vascularity, cellularity, or pleomorphism.…”

Section: Discussionmentioning

confidence: 99%

“….2.5-11.20.21 j n low-grade astrocytomas, the pattern of contrast enhancement was most often nodular, whereas in malignant tumors, enhancement was heterogeneous or the enhanced regions were multiloculated or ring-shaped. 2 ' 810 "' 21 Butler et al 1 showed that vascularity and necrosis in supratentorial gliomas correlate with contrast enhancement. Although cellularity and pleomorphism are less closely correlated with contrast enhancement, the authors suggested that the pathologic grade of a supratentorial malignant astrocytoma can be inferred from a post-contrast CT scan.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Comparison of CT Contrast Enhancement and BUDR Labeling Indices in Moderately and Highly Anaplastic Astrocytomas of the Cerebral Hemispheres

McDermott

Krouwer

Ito

et al. 1992

Can. j. neurol. sci.

View full text Add to dashboard Cite

ABSTRACT:Contrast enhancement on computerized tomography (CT) scans has been used in directing therapy for presumed intracranial gliomas. However, for moderately anaplastic astrocytomas (MOAAS) and highly anaplastic astrocytomas (HAAS), it provides no information about proliferative potential. The bromodeoxyuridine (BUDR) labeling index (LI), however, indicates proliferative potential, correlating with histologic malignancy and survival. An LI < 1% is a favorable indicator; LI > 5% suggests more aggressiveness. To determine the correlation, if any, between BUDR LI and contrast enhancement, CT scans of 71 patients with cerebral hemisphere tumors labeled with BUDR were retrospectively reviewed. Among 36 MOAAS, the BUDR LI was < 1% in 77% of enhanced tumors and 61% of unenhanced tumors. Among 35 HAAS, it was < 5% in 56% of enhanced tumors and 90% of unenhanced tumors. Therefore, contrast enhancement on CT scans does not always correctly predict proliferative potential in these tumors, and biopsy and labeling studies are recommended before therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Comparison of CT Contrast Enhancement and BUDR Labeling Indices in Moderately and Highly Anaplastic Astrocytomas of the Cerebral Hemispheres

McDermott

Krouwer

Ito

et al. 1992

Can. j. neurol. sci.

View full text Add to dashboard Cite

show abstract

“…Plasma, CSF, and tumor samples were stored at -70°C until use. Peritumoral edema was assessed based on preoperative MRI scans, according to the Steinhoff scale [5]. After an integrated diagnosis, in accordance with the 2016 WHO Classification of Tumors of the Central Nervous System [6], patients with tumors other than GBM were excluded from the observational group.…”

Section: Methodsmentioning

confidence: 99%

Brain-Derived Neurotrophic Factor (BDNF) Concentration Levels in Cerebrospinal Fluid and Plasma in Patients With Glioblastoma: A Prospective, Observational, Controlled Study

Wójtowicz,

Czarzasta,

Przepiorka

et al. 2023

Cureus

View full text Add to dashboard Cite

Objective Glioblastomas (GBMs) are among the most frequent and most malignant of untreatable brain tumors. A GBM marker could accelerate diagnosis and facilitate therapeutic monitoring. This prospective, observational, controlled study compared brain-derived neurotrophic factor (BDNF) levels in cerebrospinal fluid (CSF) and plasma between patients with GBM and a control group. Materials and methods Patients in the observational group underwent elective GBM resection (n=24, 55.8%). Control patients (n=19, 44.2%) had elective brain surgery for an unrelated, non-neoplastic, non-traumatic pathology. We measured BDNF levels in tumors, CSF, and plasma with enzyme-linked immunosorbent assay (ELISA). Peripheral blood and CSF samples were collected before surgery, and tumors were sampled intraoperatively. We analyzed correlations between BDNF levels and patient sex, age, seizures, smoking, diabetes mellitus (DM), and the use of selected antiepileptic drug (AED) and antihypertensive drug groups. Results The mean CSF BDNF concentration was significantly lower in patients with GBM (6.5 pg/mL) than in controls (11.48 pg/mL) (p=0.002). Similarly, the mean plasma BDNF concentration was significantly lower in patients with GBM (288.59 pg/mL) than in controls (574.06 pg/mL) (p=0.0005). None of the examined factors influenced CSF, plasma, or tumor tissue BDNF concentrations (p>0.05). Conclusion Plasma and CSF BDNF levels were significantly lower in adults with GBM than in controls. Thus, CSF and plasma BDNF levels may aid in GBM diagnoses. Further prospective studies are required.

show abstract

Transient neurologic disturbances, brain tumors, and normal computed tomography scans

Walker¹,

Lieberman²,

Pinto³

et al. 1983

Cancer

View full text Add to dashboard Cite

During a 4‐year period, four patients presented with transient disturbances in neurologic function that were diagnosed as seizures in two and transient ischemic attacks in the other two. Computed tomography (CT scan), both with and without contrast, was normal in all four patients. Isotopic brain scans (3 patients), cerebral angiograms (4 patients), and lumbar punctures (4 patients) were normal. Electroencephalograms (EEG) were normal in two patients and abnormal in two patients (consisting of focal slowing). Within 4.5 months, all patients developed symptoms and signs of a brain tumor, and in all four, CT scan now revealed a large mass lesion which at surgery was shown to be a malignant astrocytoma. These four patients constituted 4% of the total number of patients with malignant astrocytomas that were seen at the NYU Medical Center during this same time period. It is stressed that the CT scan may be normal early in the course of patients with brain tumors, particularly if they present with a transient disturbance in neurologic function. The first evidence of the tumor in such patients may be a slow‐wave abnormality on the EEG. Patients who are suspected of having a brain tumor should, if the initial CT scan is normal, have the scan repeated later.

show abstract

Axial transverse computerized tomography in 73 glioblastomas

Cited by 12 publications

References 1 publication

A Comparison of CT Contrast Enhancement and BUDR Labeling Indices in Moderately and Highly Anaplastic Astrocytomas of the Cerebral Hemispheres

A Comparison of CT Contrast Enhancement and BUDR Labeling Indices in Moderately and Highly Anaplastic Astrocytomas of the Cerebral Hemispheres

Brain-Derived Neurotrophic Factor (BDNF) Concentration Levels in Cerebrospinal Fluid and Plasma in Patients With Glioblastoma: A Prospective, Observational, Controlled Study

Transient neurologic disturbances, brain tumors, and normal computed tomography scans

Contact Info

Product

Resources

About